Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 58
Filter
1.
Oncotarget ; 14: 174-177, 2023 03 11.
Article in English | MEDLINE | ID: mdl-36913305

ABSTRACT

Studies on the role of transcription factor MYB in acute myeloid leukemia (AML) have identified MYB as a key regulator of a transcriptional program for self-renewal of AML cells. Recent work summarized here has now highlighted the CCAAT-box/enhancer binding protein beta (C/EBPß) as an essential factor and potential therapeutic target that cooperates with MYB and coactivator p300 in the maintenance of the leukemic cells.


Subject(s)
CCAAT-Enhancer-Binding Protein-beta , Leukemia, Myeloid, Acute , Oncogene Proteins v-myb , Humans , CCAAT-Enhancer-Binding Protein-beta/genetics , CCAAT-Enhancer-Binding Protein-beta/metabolism , Gene Expression Regulation , Leukemia, Myeloid, Acute/genetics , Oncogene Proteins v-myb/genetics , Oncogene Proteins v-myb/metabolism
2.
Aging (Albany NY) ; 13(23): 25138-25152, 2021 12 13.
Article in English | MEDLINE | ID: mdl-34898477

ABSTRACT

The long non-coding RNA (lncRNA) SNHG3 has been shown to play oncogenic roles in several cancer types, but the mechanisms underlying its activity are poorly understood. In this study, we aimed to explore the clinical relevance and mechanistic role of SNHG3 in gastric cancer (GC). We found that SNHG3 expression in GC cell lines and tissues was significantly increased, and the upregulation of this lncRNA was correlated with tumor clinical stage and decreased patient survival. Knocking down SNHG3 in GC cells impaired the proliferative, migratory, and invasive activity in vitro and constrained in vivo GC xenograft tumor growth. Mechanistically, SNHG3 was found to bind and sequester miR-139-5p, thereby indirectly promoting the upregulation of the miR-139-5p target gene MYB. These data demonstrated that SNHG3 functions in an oncogenic manner to drive GC proliferation, migration, and invasion by regulating the miR-139-5p/MYB axis.


Subject(s)
Cell Proliferation , MicroRNAs/metabolism , Oncogene Proteins v-myb/metabolism , RNA, Long Noncoding/metabolism , Stomach Neoplasms/etiology , Animals , Cell Line, Tumor , Humans , In Situ Hybridization, Fluorescence , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Middle Aged , Neoplasm Transplantation , Polymerase Chain Reaction , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology
3.
Leukemia ; 34(5): 1354-1363, 2020 05.
Article in English | MEDLINE | ID: mdl-31768017

ABSTRACT

Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an oncofetal protein expressed in various cancers including leukemia. In this study, we assessed the role of IGF2BP1 in orchestrating leukemia stem cell properties. Tumor-initiating potential, sensitivity to chemotherapeutic agents, and expression of cancer stem cell markers were assessed in a panel of myeloid, B-, and T-cell leukemia cell lines using gain- and loss-of-function systems, cross-linking immunoprecipitation (CLIP), and photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation (PAR-CLIP) techniques. Here, we report that genetic or chemical inhibition of IGF2BP1 decreases leukemia cells' tumorigenicity, promotes myeloid differentiation, increases leukemia cell death, and sensitizes leukemia cells to chemotherapeutic drugs. IGF2BP1 affects proliferation and tumorigenic potential of leukemia cells through critical regulators of self-renewal HOXB4 and MYB and through regulation of expression of the aldehyde dehydrogenase, ALDH1A1. Our data indicate that IGF2BP1 maintains leukemia stem cell properties by regulating multiple pathways of stemness through transcriptional and metabolic factors.


Subject(s)
Aldehyde Dehydrogenase 1 Family/metabolism , Gene Expression Regulation, Leukemic , Homeodomain Proteins/metabolism , Leukemia, Myeloid, Acute/pathology , Neoplastic Stem Cells/pathology , Oncogene Proteins v-myb/metabolism , RNA-Binding Proteins/metabolism , Retinal Dehydrogenase/metabolism , Transcription Factors/metabolism , Aldehyde Dehydrogenase 1 Family/genetics , Animals , Antineoplastic Agents/pharmacology , Apoptosis , Biomarkers, Tumor , Cell Proliferation , Drug Resistance, Neoplasm , Female , Homeodomain Proteins/genetics , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/metabolism , Mice , Mice, SCID , Neoplastic Stem Cells/metabolism , Oncogene Proteins v-myb/genetics , RNA-Binding Proteins/genetics , Retinal Dehydrogenase/genetics , Transcription Factors/genetics , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
4.
Clin Lab ; 65(6)2019 Jun 01.
Article in English | MEDLINE | ID: mdl-31232026

ABSTRACT

BACKGROUND: This study was designed to evaluate the effects of micro-RNA-16 (miR-16)-regulated expression of myeloblastosis oncogene (MYB) on the differentiation of acute leukemia cells, the expressions of miR-16 and MYB mRNA, and protein in differently differentiated leukemia cells were detected by real-time PCR and western blot. METHODS: 1,25-Dihydroxyvitamin D3 (1,25 D3) induced monocytic differentiation of HL60 cells, and the resulting changes in miR-16 and MYB expressions were detected. Morphology of the cells induced by 1,25 D3, after being transfection with miR-16 mimics, was observed by Wright-Giemsa staining. The expression of mononuclear cell surface marker CD14 was detected by flow cytometry. RESULTS: Minimum miR-16 was expressed in early-differentiation KG-1a cells, while late-differentiation U937 and THP-1 cells had higher expressions (p < 0.01). The expressions of MYB changed oppositely. During the monocytic differentiation of HL60 cells, miR-16 expression showed a time-dependent increase, but MYB expression gradually decreased. Overexpression of miR-16 in HL60 cells promoted 1,25 D3-induced morphological changes and CD14 expression (p < 0.05). CONCLUSIONS: MR-16 facilitated the monocytic differentiation of leukemia HL60 cells by negatively regulating MYB expression.


Subject(s)
Cell Differentiation/genetics , Leukemia, Myeloid/genetics , MicroRNAs/genetics , Oncogene Proteins v-myb/genetics , Acute Disease , Calcitriol/pharmacology , Cell Differentiation/drug effects , Cell Line, Tumor , Gene Expression Profiling , Gene Expression Regulation, Leukemic/drug effects , HL-60 Cells , Humans , K562 Cells , Leukemia, Myeloid/metabolism , Leukemia, Myeloid/pathology , Oncogene Proteins v-myb/metabolism , THP-1 Cells , U937 Cells
5.
Nucleic Acids Res ; 45(17): 9960-9975, 2017 Sep 29.
Article in English | MEDLINE | ID: mdl-28973440

ABSTRACT

Most E2F-binding sites repress transcription through the recruitment of Retinoblastoma (RB) family members until the end of the G1 cell-cycle phase. Although the MYB promoter contains an E2F-binding site, its transcription is activated shortly after the exit from quiescence, before RB family members inactivation, by unknown mechanisms. We had previously uncovered a nuclear factor distinct from E2F, Myb-sp, whose DNA-binding site overlapped the E2F element and had hypothesized that this factor might overcome the transcriptional repression of MYB by E2F-RB family members. We have purified Myb-sp and discovered that Myc-associated zinc finger proteins (MAZ) are major components. We show that various MAZ isoforms are present in Myb-sp and activate transcription via the MYB-E2F element. Moreover, while forced RB or p130 expression repressed the activity of a luciferase reporter driven by the MYB-E2F element, co-expression of MAZ proteins not only reverted repression, but also activated transcription. Finally, we show that MAZ binds the MYB promoter in vivo, that its binding site is critical for MYB transactivation, and that MAZ knockdown inhibits MYB expression during the exit from quiescence. Together, these data indicate that MAZ is essential to bypass MYB promoter repression by RB family members and to induce MYB expression.


Subject(s)
DNA-Binding Proteins/genetics , E2F Transcription Factors/genetics , G1 Phase/genetics , Gene Expression Regulation , Oncogene Proteins v-myb/genetics , Promoter Regions, Genetic , Transcription Factors/genetics , Binding Sites , Cell Line, Tumor , Crk-Associated Substrate Protein/genetics , Crk-Associated Substrate Protein/metabolism , DNA-Binding Proteins/antagonists & inhibitors , DNA-Binding Proteins/metabolism , E2F Transcription Factors/metabolism , Genes, Reporter , HEK293 Cells , Humans , Jurkat Cells , Luciferases/genetics , Luciferases/metabolism , Lymphocytes/cytology , Lymphocytes/metabolism , Oncogene Proteins v-myb/metabolism , Osteoblasts/cytology , Osteoblasts/metabolism , Protein Binding , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Retinoblastoma Protein/genetics , Retinoblastoma Protein/metabolism , Transcription Factors/antagonists & inhibitors , Transcription Factors/metabolism , Transcription, Genetic
6.
Eye (Lond) ; 31(5): 720-725, 2017 May.
Article in English | MEDLINE | ID: mdl-28085142

ABSTRACT

PurposeAdenoid cystic carcinoma (ACC) represents ~10-15% of salivary neoplasms and almost universally exhibits a lethal clinical course. ACC is also known to occur in the lacrimal gland. ACC is characterized by its heterogeneous morphology and may demonstrate tubular, cribriform, and/or solid architectural patterns. Unfortunately, these histopathological features are not specific to ACC and can be seen in other salivary gland-type neoplasms, introducing a diagnostic dilemma. The discovery of fusion transcripts has revolutionized the diagnosis, surveillance, and treatment of epithelial malignancies. In several anatomic subsites ACC is frequently characterized by a fusion transcript involving genes MYB and NFIB; more specifically, t(6;9)(q22-23;p23-24). This study explores the incidence of MYB rearrangement in cases of lacrimal gland ACC using fluorescent in situ hybridization.Materials and methodsRetrospective clinical and histopathological review of 12 cases of lacrimal gland ACC seen at Mayo Clinic over a 25-year period (1990-2015) was performed. Demographic and clinical data were obtained from medical records. Surgical pathology archival material including H&E slides and immunostains was re-examined. Formalin-fixed paraffin-embedded material was further evaluated using immunohistochemistry when appropriate. Fluorescent in situ hybridization (FISH) using a MYB break-apart probe was applied to all histologically confirmed cases of ACC and benign salivary gland parenchyma.ResultsThe median patient age was 53.6 years (range 12-64) and distributed equally by gender (six male and six female). Rearrangement of MYB was identified using FISH in seven cases (58%). Twenty-five sections of benign salivary gland parenchyma showed no evidence of MYB rearrangement. Primary surgical resection was most common treatment, and 78% of the patient received adjuvant radiation therapy. Median overall survival (OS) was 11 years. Rearrangement of MYB did not affect OS.ConclusionsIn summary, our results indicate that the MYB rearrangement defines a significant subset of lacrimal gland ACCs. Importantly, FISH for MYB rearrangement may be used as a diagnostic tool during pathological examination of lacrimal gland neoplasms. Our results showed no relationship between rearrangement status and clinical outcome. Lastly, the presence of t(6;9) in ACC may provide a platform for molecular-targeting strategies in the future.


Subject(s)
Carcinoma, Adenoid Cystic/genetics , Eye Neoplasms/genetics , Lacrimal Apparatus Diseases/genetics , Lacrimal Apparatus/pathology , Oncogene Proteins v-myb/genetics , Adolescent , Adult , Biomarkers, Tumor/genetics , Biopsy , Carcinoma, Adenoid Cystic/diagnosis , Carcinoma, Adenoid Cystic/metabolism , Child , Eye Neoplasms/diagnosis , Eye Neoplasms/metabolism , Female , Gene Rearrangement , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Lacrimal Apparatus Diseases/diagnosis , Lacrimal Apparatus Diseases/metabolism , Male , Middle Aged , Oncogene Proteins v-myb/metabolism , Retrospective Studies , Young Adult
7.
Diagn Cytopathol ; 44(10): 799-804, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27491495

ABSTRACT

BACKGROUND: Basaloid tumors of the salivary gland both benign and malignant comprise ACC, cellular PA, basal cell adenoma (BCA), and basal cell adenocarcinoma. Rendering a diagnosis given a limited biopsy or fine needle aspiration (FNA) sample proves challenging. Activation of MYB by gene fusion has been found in salivary gland ACCs; therefore we investigated the utility of MYB immunohistochemistry (IHC) as a tool for distinguishing ACCs from other basaloid neoplasms. METHODS: We selected 48 cases of ACC (11 FNA blocks [CB]), 37 histologic resections [HR]), 74 PA (36 CB, 38 HR), and 18 BCA (7 CB, 11 HR). FNA CB showed 82% of ACCs (N = 9 of 11) as positive for MYB nuclear staining whereas 68% of ACCs (N = 25 of 37) were positive in HR. RESULTS: All PA were negative for MYB nuclear staining in both CB (N = 0 of 36) and HR (N = 0 of 38). CB showed 29% of BCA (N = 2 of 7) as positive for MYB nuclear staining and 55% (N = 6 of 11) positive in HR. Both ACC and BCA showed significantly higher mean staining intensity than PA in both CB and HR (P < 0.0001). When comparing ACC and BCA, significantly higher mean staining intensity was observed in CB (P = 0.02382) but not in HR (P = 0.42952). CONCLUSION: MYB nuclear staining may prove useful in separating ACC from PA and BCA, especially in limited cellular samples. Diagn. Cytopathol. 2016;44:799-804. © 2016 Wiley Periodicals, Inc.


Subject(s)
Adenoma, Pleomorphic/pathology , Biomarkers, Tumor/metabolism , Carcinoma, Adenoid Cystic/pathology , Oncogene Proteins v-myb/metabolism , Adenoma, Pleomorphic/classification , Adenoma, Pleomorphic/metabolism , Biopsy, Fine-Needle , Carcinoma, Adenoid Cystic/classification , Carcinoma, Adenoid Cystic/metabolism , Diagnosis, Differential , Humans , Sensitivity and Specificity
8.
J Biol Chem ; 291(31): 16263-70, 2016 07 29.
Article in English | MEDLINE | ID: mdl-27246849

ABSTRACT

Extensive desmoplasia is a prominent pathological characteristic of pancreatic cancer (PC) that not only impacts tumor development, but therapeutic outcome as well. Recently, we demonstrated a novel role of MYB, an oncogenic transcription factor, in PC growth and metastasis. Here we studied its effect on pancreatic tumor histopathology and associated molecular and biological mechanisms. Tumor-xenografts derived from orthotopic-inoculation of MYB-overexpressing PC cells exhibited far-greater desmoplasia in histological analyses compared with those derived from MYB-silenced PC cells. These findings were further confirmed by immunostaining of tumor-xenograft sections with collagen-I, fibronectin (major extracellular-matrix proteins), and α-SMA (well-characterized marker of myofibroblasts or activated pancreatic stellate cells (PSCs)). Likewise, MYB-overexpressing PC cells provided significantly greater growth benefit to PSCs in a co-culture system as compared with the MYB-silenced cells. Interrogation of deep-sequencing data from MYB-overexpressing versus -silenced PC cells identified Sonic-hedgehog (SHH) and Adrenomedullin (ADM) as two differentially-expressed genes among others, which encode for secretory ligands involved in tumor-stromal cross-talk. In-silico analyses predicted putative MYB-binding sites in SHH and ADM promoters, which was later confirmed by chromatin-immunoprecipitation. A cooperative role of SHH and ADM in growth promotion of PSCs was confirmed in co-culture by using their specific-inhibitors and exogenous recombinant-proteins. Importantly, while SHH acted exclusively in a paracrine fashion on PSCs and influenced the growth of PC cells only indirectly, ADM could directly impact the growth of both PC cells and PSCs. In summary, we identified MYB as novel regulator of pancreatic tumor desmoplasia, which is suggestive of its diverse roles in PC pathobiology.


Subject(s)
Adrenomedullin/biosynthesis , Gene Expression Regulation, Neoplastic , Hedgehog Proteins/biosynthesis , Oncogene Proteins v-myb/metabolism , Pancreatic Neoplasms/metabolism , Paracrine Communication , Response Elements , Transcription, Genetic , Up-Regulation , Adrenomedullin/genetics , Animals , Cell Line, Tumor , Hedgehog Proteins/genetics , Heterografts , Humans , Mice , Neoplasm Transplantation , Oncogene Proteins v-myb/genetics , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Pancreatic Stellate Cells/metabolism , Pancreatic Stellate Cells/pathology
9.
J Oral Pathol Med ; 45(9): 698-703, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26711587

ABSTRACT

BACKGROUND: In practices, some cases of salivary basal cell tumors that consist mainly of cribriform growth pattern are difficult to differentiate from adenoid cystic carcinoma (AdCC). Identification of reliable molecular biomarkers for the differential diagnosis between them is required. METHODS: Twenty-two cases of cribriform salivary basal cell tumors (at least 10% cribriform pattern present in each tumor) comprising 18 cases of basal cell adenoma (BCA) and four cases of basal cell adenocarcinoma (BcAC) were collected between 1985 and 2008. Twenty cases of cribriform AdCC were retrieved from our archives. MYB protein expression and gene abnormalities were detected in all cases by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) analyses, respectively. RESULTS: Neither MYB protein nor split genes were detected in any of the cases of cribriform basal cell tumors, while 55% (11/20) of cases of cribriform AdCC had MYB protein expression. High MYB expression was detected in 81.8% (9/11) cases, while low expression was found in the remaining cases. FISH analysis indicated that nine AdCC tumors with high MYB protein expression were split gene-positive, while MYB gene splitting was not detected in the 11 cases with low or absent MYB protein expression. CONCLUSION: The molecular changes in AdCC differ from those associated with cribriform basal cell tumors, which further confirms that cribriform basal cell tumors and AdCC are two distinct tumor entities. Simultaneous detection of MYB protein expression and the associated molecular changes could be beneficial in differentiating salivary cribriform basal cell tumors from AdCC.


Subject(s)
Adenocarcinoma/genetics , Carcinoma, Adenoid Cystic/genetics , Genes, myb/genetics , Salivary Gland Neoplasms/genetics , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Biomarkers, Tumor/analysis , Carcinoma, Adenoid Cystic/diagnosis , Carcinoma, Adenoid Cystic/pathology , Diagnosis, Differential , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Oncogene Proteins v-myb/metabolism , Salivary Gland Neoplasms/diagnosis , Salivary Gland Neoplasms/pathology
10.
Respir Res ; 16: 22, 2015 Feb 13.
Article in English | MEDLINE | ID: mdl-25763778

ABSTRACT

BACKGROUND: The transcription factor NK2 homeobox 1 (Nkx2-1) plays essential roles in epithelial cell proliferation and differentiation in mouse and human lung development and tumorigenesis. A better understanding of genes and pathways downstream of Nkx2-1 will clarify the multiple roles of this critical lung factor. Nkx2-1 regulates directly or indirectly numerous protein-coding genes; however, there is a paucity of information about Nkx2-1-regulated microRNAs (miRNAs). METHODS AND RESULTS: By miRNA array analyses of mouse epithelial cell lines in which endogenous Nkx2-1 was knocked-down, we revealed that 29 miRNAs were negatively regulated including miR-200c, and 39 miRNAs were positively regulated by Nkx2-1 including miR-1195. Mouse lungs lacking functional phosphorylated Nkx2-1 showed increased expression of miR-200c and alterations in the expression of other top regulated miRNAs. Moreover, chromatin immunoprecipitation assays showed binding of NKX2-1 protein to regulatory regions of these miRNAs. Promoter reporter assays indicated that 1kb of the miR-200c 5' flanking region was transcriptionally active but did not mediate Nkx2-1- repression of miR-200c expression. 3'UTR reporter assays support a direct regulation of the predicted targets Nfib and Myb by miR-200c. CONCLUSIONS: These studies suggest that Nkx2-1 controls the expression of specific miRNAs in lung epithelial cells. In particular, we identified a regulatory link between Nkx2-1, the known tumor suppressor miR-200c, and the developmental and oncogenic transcription factors Nfib and Myb, adding new players to the regulatory mechanisms driven by Nkx2-1 in lung epithelial cells that may have implications in lung development and tumorigenesis.


Subject(s)
Cell Transformation, Neoplastic/metabolism , Epithelial Cells/metabolism , Lung/metabolism , MicroRNAs/metabolism , NFI Transcription Factors/metabolism , Nuclear Proteins/metabolism , Oncogene Proteins v-myb/metabolism , Transcription Factors/metabolism , 3' Untranslated Regions , 5' Flanking Region , Animals , Binding Sites , Cell Line , Cell Transformation, Neoplastic/genetics , Gene Expression Profiling , Gene Expression Regulation, Developmental , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Genes, Reporter , Mice , MicroRNAs/genetics , NFI Transcription Factors/genetics , Nuclear Proteins/deficiency , Nuclear Proteins/genetics , Oncogene Proteins v-myb/genetics , Phosphorylation , Promoter Regions, Genetic , Thyroid Nuclear Factor 1 , Transcription Factors/deficiency , Transcription Factors/genetics , Transcription, Genetic , Transfection
11.
Tissue Cell ; 46(5): 352-5, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25064514

ABSTRACT

The Myb transcription factors are involved in essential cellular processes, such as cell proliferation, differentiation and cell death. Biological functions carried out by specific Myb proteins are distinct. Hair follicles are ectodermal-derived organs with cycling character of the growth resulting from the presence of somatic stem cells. In this study, we followed the expression of the Myb proteins in developing hair follicles and in the hair follicle stem cell niche by immunofluorescence staining. During hair follicle development, B-Myb was present in a few cells located in the area of cell division; c-Myb was abundant postanally in dividing cells but also in keratinizing zone. In addition, c-Myb was also detected in cells under the hair follicle bulge. These findings indicate possible involvement of c-Myb in regulation of activated stem cells leaving the niche.


Subject(s)
Hair Follicle/metabolism , Oncogene Proteins v-myb/metabolism , Animals , Fluorescent Antibody Technique , Hair Follicle/embryology , Hair Follicle/growth & development , Mice
12.
Am J Hematol ; 89(1): 25-33, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23963825

ABSTRACT

Nasal NK/T-cell lymphoma (NNKTL) is an Epstein-Barr virus (EBV)-associated malignancy and has distinct clinical and histological features. However, its genetic features are hitherto unclear. MicroRNAs (miRNAs) play a crucial role in the pathogenesis of several malignancies via regulating gene expression. In this study, we investigated whether the specific microRNAs were related to the tumor behaviors in NNKTL. MiRNA array and Quantitative RT-PCR analyses revealed that miR-15a was expressed at a much lower level in NNKTL cells (SNK-1, SNK-6, and SNT-8) than in normal peripheral NK cells and EBV-negative NK cell line KHYG-1. Quantitative PCR and western blot analyses showed that the expression of MYB and cyclin D1, which are validated targets of miR-15a, was higher in NNKTL cells. Transfection of NNKTL cells (SNK-6 and SNT-8) with a miR-15a precursor decreased MYB and cyclin D1 levels, thereby blocking G1/S transition and cell proliferation. Knockdown of EBV-encoded latent membrane protein 1 (LMP1) significantly increased miR-15a expression in SNK-6 cells. In NNKTL tissues, we found that reduced miR-15a expression, which correlated with MYB and cyclin D1 expression, was associated with poor prognosis of NNKTL patients. These data suggest that downregulation of miR-15a, possibly due to LMP1, implicates in the pathogenesis of NNKTL by inducing cell proliferation via MYB and cyclin D1. Thus, miR-15a could be a potential target for antitumor therapy and a prognostic predictor for NNKTL.


Subject(s)
Gene Expression Regulation, Neoplastic , Lymphoma, Extranodal NK-T-Cell/genetics , Lymphoma, Extranodal NK-T-Cell/mortality , MicroRNAs/genetics , Viral Matrix Proteins/genetics , Adult , Aged , Aged, 80 and over , Cell Cycle Checkpoints/genetics , Cell Line, Tumor , Cell Proliferation , Cyclin D1/genetics , Cyclin D1/metabolism , Down-Regulation , Female , Humans , Lymphoma, Extranodal NK-T-Cell/pathology , Male , MicroRNAs/metabolism , Middle Aged , Neoplasm Staging , Oncogene Proteins v-myb/genetics , Oncogene Proteins v-myb/metabolism , Prognosis , Viral Matrix Proteins/metabolism
13.
Oncogene ; 33(39): 4735-45, 2014 Sep 25.
Article in English | MEDLINE | ID: mdl-24121269

ABSTRACT

PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor suppressor that is often mutated in human hematologic malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not cause AML in mouse. Deletion of p53 in the PU.1(ure/ure) mice (PU.1(ure/ure)p53(-/-)) results in more aggressive AML with shortened overall survival. PU.1(ure/ure)p53(-/-) progenitors express significantly lower PU.1 levels. In addition to URE deletion we searched for other mechanisms that in the absence of p53 contribute to decreased PU.1 levels in PU.1(ure/ure)p53(-/-) mice. We found involvement of Myb and miR-155 in downregulation of PU.1 in aggressive murine AML. Upon inhibition of either Myb or miR-155 in vitro the AML progenitors restore PU.1 levels and lose leukemic cell growth similarly to PU.1 rescue. The MYB/miR-155/PU.1 axis is a target of p53 and is activated early after p53 loss as indicated by transient p53 knockdown. Furthermore, deregulation of both MYB and miR-155 coupled with PU.1 downregulation was observed in human AML, suggesting that MYB/miR-155/PU.1 mechanism may be involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.


Subject(s)
Leukemia, Myeloid, Acute/genetics , Proto-Oncogene Proteins/genetics , Trans-Activators/genetics , Tumor Suppressor Protein p53/genetics , Animals , Disease Models, Animal , Gene Expression Regulation, Leukemic , Humans , Leukemia, Myeloid, Acute/pathology , Liver/pathology , Mice , Mice, Knockout , MicroRNAs/genetics , MicroRNAs/metabolism , Oncogene Proteins v-myb/genetics , Oncogene Proteins v-myb/metabolism , Promoter Regions, Genetic , Proto-Oncogene Proteins c-myc/genetics , Proto-Oncogene Proteins c-myc/metabolism , Spleen/pathology , Transcriptional Activation
14.
Oncogene ; 33(35): 4442-9, 2014 Aug 28.
Article in English | MEDLINE | ID: mdl-24121275

ABSTRACT

The MYB gene is a master regulator of hematopoiesis and contributes to leukemogenesis in several species including humans. Although it is clear that MYB can promote proliferation, suppress apoptosis and block differentiation, the identities of the MYB target genes that mediate these effects have only been partially elucidated. Several studies, including our own, have collectively identified substantial numbers of MYB target genes, including candidates for each of these activities; however, functional validation, particularly in the case of differentiation suppression, has lagged well behind. Here we show that GFI1, which encodes an important regulator of hematopoietic stem cell (HSC) function and granulocytic differentiation, is a direct target of MYB in myeloid leukemia cells. Chromatin immunoprecipitation and reporter studies identified a functional MYB-binding site in the promoter region of GFI, whereas ectopic expression and small hairpin RNA-mediated knockdown of MYB resulted in concomitant increases and decreases, respectively, in GFI1 expression. We also demonstrate that GFI1, like MYB, can block the induced monocytic differentiation of a human acute myeloid leukemia cell line, and most importantly, that GFI1 is essential for MYB's ability to block monocytic differentiation. Thus, we have identified a target of MYB that is a likely mediator of its myeloid differentiation-blocking activity, and which may also be involved in MYB's activities in regulating normal HSC function and myeloid differentiation.


Subject(s)
DNA-Binding Proteins/genetics , Leukemia, Myeloid, Acute/pathology , Monocytes/physiology , Oncogene Proteins v-myb/metabolism , Transcription Factors/genetics , Cell Differentiation , DNA-Binding Proteins/metabolism , Gene Expression Regulation, Neoplastic , Humans , Leukemia, Myeloid, Acute/genetics , Monocytes/pathology , Oncogene Proteins v-myb/genetics , Promoter Regions, Genetic , Proto-Oncogene Mas , Transcription Factors/metabolism , Transcriptional Activation , U937 Cells
15.
Blood Cells Mol Dis ; 52(1): 68-75, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23910958

ABSTRACT

The BCL6 gene, which is expressed in certain B- and T-cell human lymphomas, is involved with chromosomal rearrangements and mutations in a number of these neoplasms. Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors. We used retroviral insertional mutagenesis in transgenic mice expressing the human BCL6 transgene in order to identify genes that cooperate with BCL6 during lymphomatous transformation. We previously reported PIM1 as the most frequently recurring cooperating gene in this model. We now report three newly identified cooperating genes-GFI1B, EVI5, and MYB-that we identified in the lymphomas of retroviral-injected BCL6 transgenic mice (but not in retroviral-injected non-transgenic controls); mRNA and protein expression of GFI1B and EVI5 were decreased in the murine tumors, whereas MYB mRNA and protein expression were increased or decreased. These findings correlated with protein expression in human lymphomas, both B- and T-cell. Improved therapy of lymphomas may necessitate the development of combinations of drugs that target the alterations specific to each neoplasm.


Subject(s)
DNA-Binding Proteins/genetics , Gene Expression Regulation, Neoplastic , Lymphoma, B-Cell/genetics , Lymphoma, T-Cell/genetics , Oncogene Proteins v-myb/genetics , Proto-Oncogene Proteins/genetics , Repressor Proteins/genetics , Transcription Factors/genetics , Animals , Cell Cycle Proteins , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Cell Transformation, Neoplastic/pathology , DNA-Binding Proteins/metabolism , Female , GTPase-Activating Proteins , Genetic Vectors , Humans , Immunohistochemistry , Lymphoma, B-Cell/metabolism , Lymphoma, B-Cell/pathology , Lymphoma, T-Cell/metabolism , Lymphoma, T-Cell/pathology , Male , Mice , Mice, Transgenic , Oncogene Proteins v-myb/metabolism , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-bcl-6 , RNA, Messenger/genetics , RNA, Messenger/metabolism , Repressor Proteins/metabolism , Retroviridae/genetics , Signal Transduction , Transcription Factors/metabolism
16.
PLoS One ; 8(5): e63187, 2013.
Article in English | MEDLINE | ID: mdl-23650552

ABSTRACT

The microtubule-dependent molecular motor KIF23 (Kinesin family member 23) is one of two components of the centralspindlin complex assembled during late stages of mitosis. Formation of this complex is known as an essential step for cytokinesis. Here, we identified KIF23 as a new transcriptional target gene of the tumor suppressor protein p53. We showed that p53 reduces expression of KIF23 on the mRNA as well as the protein level in different cell types. Promoter reporter assays revealed that this repression results from downregulation of KIF23 promoter activity. CDK inhibitor p21(WAF1/CIP1) was shown to be necessary to mediate p53-dependent repression. Furthermore, we identified the highly conserved cell cycle genes homology region (CHR) in the KIF23 promoter to be strictly required for p53-dependent repression as well as for cell cycle-dependent expression of KIF23. Cell cycle- and p53-dependent regulation of KIF23 appeared to be controlled by differential binding of DREAM and MMB complexes to the CHR element. With this study, we describe a new mechanism for transcriptional regulation of KIF23. Considering the strongly supporting function of KIF23 in cytokinesis, its p53-dependent repression may contribute to the prevention of uncontrolled cell growth.


Subject(s)
Gene Silencing , Kv Channel-Interacting Proteins/metabolism , Microtubule-Associated Proteins/genetics , Oncogene Proteins v-myb/metabolism , Promoter Regions, Genetic , Repressor Proteins/metabolism , Tumor Suppressor Protein p53/metabolism , Animals , Cell Cycle , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Gene Expression Regulation , HCT116 Cells , Humans , Mice , Microtubule-Associated Proteins/metabolism , NIH 3T3 Cells , Protein Binding , Protein Isoforms/genetics , Protein Isoforms/metabolism , Protein Stability , RNA, Messenger/genetics , RNA, Messenger/metabolism , Response Elements , Transcription, Genetic
17.
Leuk Res ; 37(5): 595-601, 2013 May.
Article in English | MEDLINE | ID: mdl-23398943

ABSTRACT

RNA interference-mediated suppression of MYB expression promoted apoptosis in the AML cell line U937, without affecting expression of the anti-apoptotic MYB target BCL2. This was accompanied by up-regulation of the pro-apoptotic gene DRAK2 and stimulation of caspase-9 activity. Moreover, RNA interference-mediated suppression of DRAK2 in U937 cells alleviated apoptosis induced by MYB down-regulation. Finally ChIP assays showed that in U937 cells MYB binds to a conserved element upstream of the DRAK2 transcription start site. Together, these findings identify a novel mechanism by which MYB suppresses apoptosis in an AML model cell line.


Subject(s)
Apoptosis Regulatory Proteins/biosynthesis , Apoptosis , Gene Expression Regulation, Leukemic , Leukemia, Myeloid, Acute/metabolism , Oncogene Proteins v-myb/metabolism , Protein Serine-Threonine Kinases/biosynthesis , Transcription, Genetic , Apoptosis Regulatory Proteins/genetics , Caspase 9/genetics , Caspase 9/metabolism , Down-Regulation/genetics , Humans , K562 Cells , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/pathology , Oncogene Proteins v-myb/genetics , Protein Serine-Threonine Kinases/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Response Elements/genetics , U937 Cells
18.
Genes Dev ; 26(5): 474-89, 2012 Mar 01.
Article in English | MEDLINE | ID: mdl-22391450

ABSTRACT

Cell cycle progression is dependent on two major waves of gene expression. Early cell cycle gene expression occurs during G1/S to generate factors required for DNA replication, while late cell cycle gene expression begins during G2 to prepare for mitosis. Here we demonstrate that the MuvB complex-comprised of LIN9, LIN37, LIN52, LIN54, and RBBP4-serves an essential role in three distinct transcription complexes to regulate cell cycle gene expression. The MuvB complex, together with the Rb-like protein p130, E2F4, and DP1, forms the DREAM complex during quiescence and represses expression of both early and late genes. Upon cell cycle entry, the MuvB complex dissociates from p130/DREAM, binds to B-Myb, and reassociates with the promoters of late genes during S phase. MuvB and B-Myb are required for the subsequent recruitment of FoxM1 to late gene promoters during G2. The MuvB complex remains bound to FoxM1 during peak late cell cycle gene expression, while B-Myb binding is lost when it undergoes phosphorylation-dependent, proteasome-mediated degradation during late S phase. Our results reveal a novel role for the MuvB complex in recruiting B-Myb and FoxM1 to promote late cell cycle gene expression and in regulating cell cycle gene expression from quiescence through mitosis.


Subject(s)
Forkhead Transcription Factors/metabolism , Gene Expression Regulation, Neoplastic , Mitosis/physiology , Oncogene Proteins v-myb/metabolism , Cell Cycle/physiology , Cell Line, Tumor , Forkhead Box Protein M1 , Genome-Wide Association Study , HeLa Cells , Humans , Kv Channel-Interacting Proteins/metabolism , Mitosis/genetics , Phosphorylation , Promoter Regions, Genetic , Protein Binding , Repressor Proteins/metabolism
19.
J Biol Chem ; 287(6): 3733-50, 2012 Feb 03.
Article in English | MEDLINE | ID: mdl-22167200

ABSTRACT

The protozoan Giardia lamblia parasitizes the human small intestine to cause diseases. It undergoes differentiation into infectious cysts by responding to intestinal stimulation. How the activated signal transduction pathways relate to encystation stimulation remain largely unknown. During encystation, genes encoding cyst wall proteins (CWPs) are coordinately up-regulated by a Myb2 transcription factor. Because cell differentiation is linked to cell cycle regulation, we tried to understand the role of cell cycle regulators, cyclin-dependent kinases (Cdks), in encystation. We found that the recombinant Myb2 was phosphorylated by Cdk-associated complexes and the levels of phosphorylation increased significantly during encystation. We have identified a putative cdk gene (cdk2) by searching the Giardia genome database. Cdk2 was found to localize in the cytoplasm with higher expression during encystation. Interestingly, overexpression of Cdk2 resulted in a significant increase of the levels of cwp gene expression and cyst formation. In addition, the Cdk2-associated complexes can phosphorylate Myb2 and the levels of phosphorylation increased significantly during encystation. Mutations of important catalytic residues of Cdk2 resulted in a significant decrease of kinase activity and ability of inducing cyst formation. Addition of a Cdk inhibitor, purvalanol A, significantly decreased the Cdk2 kinase activity and the levels of cwp gene expression and cyst formation. Our results suggest that the Cdk2 pathway may be involved in phosphorylation of Myb2, leading to activation of the Myb2 function and up-regulation of cwp genes during encystation. The results provide insights into the use of Cdk inhibitory drugs in disruption of Giardia differentiation into cysts.


Subject(s)
Cyclin-Dependent Kinase 2/metabolism , Giardia lamblia/metabolism , Oncogene Proteins v-myb/metabolism , Protozoan Proteins/metabolism , Transcription Factors/metabolism , Cyclin-Dependent Kinase 2/genetics , Cytoplasm/genetics , Cytoplasm/metabolism , Giardia lamblia/genetics , Humans , Oncogene Proteins v-myb/genetics , Phosphorylation , Protozoan Proteins/biosynthesis , Protozoan Proteins/genetics , Transcription Factors/genetics
20.
Biochim Biophys Acta ; 1819(1): 67-77, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22067744

ABSTRACT

Members of the MYB family of transcription factors are found in all eukaryotic lineages, where they function to regulate either fundamental cellular processes, or specific facets of metabolism or cellular differentiation. MYB transcription factors regulate these processes through modulation of transcription at target genes, to which they bind in a sequence-specific manner. Over the past decades, insights have been gained into the molecular interactions between MYB proteins and their cognate DNA targets. This review focuses on those insights, the emergence of common themes in DNA binding by diverse MYB family members. The review also considers gaps in the current knowledge of MYB-DNA interactions, particularly for plant MYB proteins, and how emerging techniques that examine protein-DNA interactions can fill these gaps.


Subject(s)
Arabidopsis/genetics , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Oncogene Proteins v-myb/genetics , Regulatory Sequences, Nucleic Acid/genetics , Repetitive Sequences, Amino Acid/genetics , Animals , Arabidopsis/metabolism , Binding Sites , Gene Expression Regulation , Multigene Family/genetics , Oncogene Proteins v-myb/classification , Oncogene Proteins v-myb/metabolism , Phylogeny , Protein Structure, Tertiary/genetics , Transcription Factors/genetics , Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...